Janssen Reports P-IIb Trial (FRONTIER 1) Results of JNJ-2113 for Moderate-to-Severe Plaque Psoriasis
Shots:
- The P-IIb trial evaluating three (25/50/100, qd) & two (25 & 100mg, BID) dosages of JNJ-2113 (IL-23R antagonist peptide) vs PBO in 255 adult patients
- The trial achieved all primary & secondary efficacy EPs i.e., patients who received JNJ-2113 achieved PASI 75 (37.2% at 25mg, qd)/(51.2% at 25mg, BID)/(58.1% at 50mg, qd)/(65.1% at 100mg, qd)/(78.6% at 100mg, BID) over 9.3% in PBO, PASI 90 (25.6%/26.8%/51.2%/46.5%/59.5% vs 2.3%) and PASI 100 (11.6%/9.8%/25.6%/23.3%/40.5% vs 0%), respectively, 100% improvement in skin clearance at highest dose level at 16wk.
- The therapy was well tolerated, patients experienced one or more AEs was 52.4% vs 51.2%, and no evidence of a dose-dependent increase in the occurrence of specific AEs was reported
Ref: PR Newswire | Image: Janssen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
